Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00851227 · ClinicalTrials.gov registry record · Phase 1
Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function
A Phase 1 study of Liver Disease and Hyponatremia, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00851227 is a Phase 1 study of Liver Disease and Hyponatremia that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 26 participants, below the 794-participant average among 14 other Liver Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00851227, a Phase 1 study of Liver Disease and Hyponatremia, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and moderate liver impairment versus subjects with normal liver function
Conditions Studied
Interventions
- DRUG conivaptan hydrochloride
Study Locations (1)
Florida
- - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00851227
The ClinicalTrials.gov registry entry for NCT00851227 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 794-participant average among 14 other Liver Disease trials with a reported enrollment target (97% lower). The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which conivaptan hydrochloride is the first listed.
NCT00851227 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00851227 about?
NCT00851227 is a clinical study titled "Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function". A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and moderate liver impairment versus subjects with normal liver function
What is the current status of trial NCT00851227?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2009-02. Estimated completion is 2010-01.
What conditions does trial NCT00851227 study?
This clinical trial studies the following conditions: Liver Disease, Hyponatremia.
What interventions are being tested in trial NCT00851227?
The interventions under investigation include: conivaptan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00851227?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00851227 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hepatic Impairment Study
COMPLETED · Phase 1
-
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
COMPLETED · Phase 1
-
A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects
COMPLETED · Phase 1
-
Evaluation of Patients With Liver Disease
RECRUITING
-
Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease
ACTIVE NOT RECRUITING
-
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.